Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PATAS - AdipoPharma

Next Previous
Drug Profile

PATAS - AdipoPharma

Alternative Names: Peptide derived from PKC alpha Targeting AlmS - AdipoPharma; Peptide-mimic of PKC Alpha Targeting ALMS - AdipoPharma

Latest Information Update: 15 Nov 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator INSERM; Monash University; University of Birmingham; University of Strasbourg
  • Class Antihyperglycaemics; Peptides
  • Mechanism of Action Adipocyte modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Type 2 diabetes mellitus

Most Recent Events

  • 11 Nov 2024 AdipoPharma plans a phase I trial for Type 2 diabetes mellitus, in mid-2025
  • 30 Jan 2023 AdipoPharma plans a phase Ia trial for Type 2 diabetes mellitus in 2023
  • 05 Aug 2022 AdipoPharma plans to file IND application with the US FDA by the first quarter of 2023 for a phase Ia trial in Type 2 diabetes later in 2023

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top